Advertisement
Advertisement

SPRY

SPRY logo

ARS Pharmaceuticals, Inc. Common Stock

6.16
USD
Sponsored
+0.61
+10.99%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

6.17

+0.01
+0.24%

ARS Pharmaceuticals, Inc. Common Stock Profile

About

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.

Info & Links

CEO

Richard Lowenthal

Headquarters

11682 El Camino Real, Suite 120
San Diego, CA 92130, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

https://ars-pharma.com

Auditor

Ernst & Young LLP

Share holders

13

Employees

163

ARS Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

613.20M

Enterprise Value

760.07M

Enterprise Value/EBITDA(ttm)

-3.70

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

6.18

Price to Book(mrq)

9.98

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

73.37%

Operating Margin(ttm)

-200.00%

Profit Margin(ttm)

-214.42%

Return on Equity(ttm)

-153.61%

Return on Invested Capital(ttm)

-73.86%

Return on Assets(ttm)

-60.85%

Income Statement

Revenue(ttm)

98.99M

Revenue Per Share(ttm)

1.00

Gross Profit(ttm)

73.37M

EBITDA(ttm)3

-205.48M

Net Income Available to Common(ttm)

-198.07M

Diluted EPS(ttm)

-2.01

Share Statistics

Beta (5Y Monthly)

0.98

52-Week Change

-65.10%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

99.30M

Dividend Yield

0.00%

Float4

65.74M

% Held by Insiders

33.80%

% Held by Institutions

68.16%

Balance Sheet

Total Cash(mrq)

200.97M

Total Cash Per Share(mrq)

2.02

Total Debt(mrq)

171.19M

Total Debt/Equity(mrq)

279.24%

Current Ratio(mrq)

4.94%

Quick Ratio(mrq)

4.77%

Book Value Per Share(mrq)

0.62

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.45

Free Cash Flow(ytd)

-44.95M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement